Orion OyjORINF +4.81%97 Net Current Asset Value is $3.73 as of Mar. 2026, which is 83% below its 10-year median of 21.51. GuruFocus rates ORINF with a GF Score™ of 97/100 and a GF Value™ of $80.82. The stock has 3 warning signs investors should review. Among 613 Drug Manufacturers companies, Orion Oyj ranks worse than 84.99% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Orion Oyj's net current asset value per share for the quarter that ended in Mar. 2026 was $3.73.
The historical rank and industry rank for Orion Oyj's Net Current Asset Value or its related term are showing as below:
ORINF'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 12.02 Med: 21.51 Max: 59.03
Current: 22.18
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Orion Oyj was 59.03. The lowest was 12.02. And the median was 21.51.
ORINF's Price-to-Net-Current-Asset-Value is ranked worse than 84.99% of 613
companies
in the Drug Manufacturers industry
Industry Median: 5.71
vs ORINF: 22.18
Orion Oyj (OTCPK:ORINF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Orion Oyj Net Current Asset Value Related Terms
Orion Oyj Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Orion Oyj's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ORINF vs LLY, JNJ, ABBV: Net Current Asset Value Comparison
For the Drug Manufacturers - General subindustry, Orion Oyj's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Oyj Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Oyj's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Orion Oyj's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $3.73 mean?
Orion Oyj (ORINF) has a Net Current Asset Value of $3.73 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Orion Oyj and its competitors. This is 83% below median its historical median of 21.51. Over the past decade, Orion Oyj's Net Current Asset Value has ranged from 12.02 to 59.03. According to the industry distribution chart, Orion Oyj ranks #521 out of 613 companies in the Drug Manufacturers industry, placing it in the top 85%.
Is Orion Oyj's Net Current Asset Value too high?
Orion Oyj's current Net Current Asset Value of $3.73 is 83% below median its 10-year median of 21.51. Over the past 10 years, this metric has ranged from a low of 12.02 to a high of 59.03. The Drug Manufacturers industry median Net Current Asset Value is 5.71. Orion Oyj's value of $3.73 is 34.7% below this industry median. Based on the distribution chart, Orion Oyj ranks #521 out of 613 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Orion Oyj has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Orion Oyj's Net Current Asset Value compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Orion Oyj ranks #521 out of 613 companies for Net Current Asset Value. This places Orion Oyj in the lower half of its industry. The industry median Net Current Asset Value is 5.71. Orion Oyj's value of $3.73 is 34.7% below this benchmark. Historically, Orion Oyj's own Net Current Asset Value has ranged from 12.02 to 59.03 over the past decade. While the company's 10-year median is 21.51 vs. the industry median of 5.71, Orion Oyj has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.71, based on 613 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Oyj's current Net Current Asset Value of $3.73 is 34.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Orion Oyj and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Oyj's current Net Current Asset Value is $3.73, which is 83% below median its own 10-year median of 21.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Oyj stock overvalued right now?
Orion Oyj (ORINF) has a current Net Current Asset Value of $3.73. The stock's GF Value™ is $80.82, compared to a current price of $82.75 — trading 2.4% above its estimated fair value. The current Net Current Asset Value is $3.73, which is 83% below median its 10-year median of 21.51 and 34.7% below the Drug Manufacturers industry median of 5.71. Orion Oyj's overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Orion Oyj (ORINF), the current Net Current Asset Value is $3.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Oyj (ORINF) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Oyj stock appears to be overvalued.
The current stock price of $82.75 is trading 2.4% above its estimated GF Value™ of $80.82.
Key valuation signals for ORINF:
Net Current Asset Value: $3.73 (83% below median its 10-year median of 21.51)
GF Value™: $80.82 vs. price of $82.75 (2.4% above fair value)
Industry Position: 34.7% below the Drug Manufacturers median (#521 of 613)
No single metric tells the full story. See the ORINF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company predominantly focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. The company mainly serves Finland but also has a presence in other European countries, North America and other countries.
97GF Score
Get the complete analysis for ORINF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORINF has been successfully added to your 
